SEC Form 4 · accession 0001104659-18-069597
Inspire Medical Systems, Inc. · INSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Randy Ban
Officer — Senior VP, Sales and Marketing
Period of report
Nov 19, 2018
Accepted (ET)
Nov 21, 2018 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609550
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 19, 2018 | M | 10,000 | $1.47 | A | 40,974 | D | |
| Common StockF2 | Nov 19, 2018 | S | 2,156 | $40.0235 | D | 38,818 | D | |
| Common StockF3 | Nov 19, 2018 | S | 2,244 | $41.041 | D | 36,574 | D | |
| Common StockF4 | Nov 19, 2018 | S | 300 | $42.235 | D | 36,274 | D | |
| Common Stock | Nov 19, 2018 | S | 300 | $43.04 | D | 35,974 | D | |
| Common StockF5 | Nov 20, 2018 | S | 3,268 | $39.6084 | D | 32,706 | D | |
| Common StockF6 | Nov 20, 2018 | S | 1,632 | $40.5622 | D | 31,074 | D | |
| Common Stock | Nov 20, 2018 | S | 100 | $41.32 | D | 30,974 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $1.47 | Nov 19, 2018 | M | 10,000 | D | — | Apr 30, 2022 | Common Stock | 10,000 | 46,390 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.51 to $ $40.50. The reporting person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.68 to $ $41.30. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.98 to $ $42.62. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.20 to $ 40.18. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.23 to $41.22. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The option is fully vested and exercisable.